Autolus Therapeutics Ltd (AUTL)

Autolus Therapeutics Ltd (AUTL) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $482M; returns 1 day -2.5%, 1 week -3.8%, 1 year +2.7%.

Autolus Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on developing next-generation programmed T cell therapies for cancer and autoimmune diseases. The company's key product is AUCATZYL® (obecabtagene autoleucel, obe-cel), a CD19-directed CAR T-cell therapy approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) in adults.

Groups AUTL belongs to

• Biotechnology
• Biopharmaceutical
• United Kingdom Companies
• Healthcare
• Oncology
• Cancer Therapeutics
• Autologous Cell Therapy
• Clinical Stage Biopharma
• Commercial Stage Biotech
• Life Sciences
• Immunotherapy
• Autoimmune Diseases
• Clinical Stage
• Hematologic Malignancies
• Hematology

AUTL financial model: income statement, cash flow and balance sheet